Skip to main content








Prentice Stovall, Jr. serves as the Global Development Leader for a molecule currently being studied for the treatment of multiple immune diseases. In this role at Lilly, Prentice is responsible and accountable for the strategic direction of the molecule across the value chain, which includes the integration of medical with marketing, regulatory, manufacturing, clinical operations, patient safety, finance, and other functions as needed for the development and realization of the molecule’s strategy, lifecycle, and development plan.

Prentice has held a wide range of progressive roles across multiple therapeutic areas during his 15+ years in the pharmaceutical industry, including marketing, market research, forecasting, sales, and drug development. This includes successfully leading pre-launch, launch, and late lifecycle assets. He has spent time living outside of the U.S., leading the oncology business in Canada, and serving on Lilly Canada’s leadership team. He served as the chair of the African American Network (AAN), one of the largest employee resource groups at Lilly, accelerating the diversity and inclusion efforts for the company and in the community. He has recently taken on a leadership role with enableUS, an employee resource group at Lilly that is focused on elevating the voice of people with disabilities.

Prentice currently serves on the Board of Directors for Children’s Bureau, Inc., a private nonprofit that has served children and families in Indiana since 1851.

Prior to Lilly, Prentice received his Bachelor of Science from Purdue University and his Master of Business Administration from the Krannert School of Management.